SynAct Pharma AB
The answer first
Does SynAct Pharma beat the market?
No, SynAct Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 9% of Nordic stocks
- Quality53
- Value3
- Trend24
No. 164 of 195 in healthcare
Max for seven days
Follow SynAct Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about SynAct Pharma
Your first answer is free, no account needed.
Do you own SynAct Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with SynAct Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- SynAct Pharma has fallen 36.3% over the past year, including dividends.
- Overall, SynAct Pharma ranks better than 9% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 95.7%. The price is 90.5% below its peak now.
What do analysts think of SynAct Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 9% of Nordic stocks.
No. 164 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 120 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.33
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−72.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 179 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity5.1
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 114 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−29.7%
- 6 months−3.0%
- 9 months−33.3%
- 12 months−36.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own SynAct Pharma
5 funds we follow own SynAct Pharma. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About SynAct Pharma
SynAct Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 8 employees.
SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.


See the full analysis of SynAct Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card